Professor Edvinas Orentas clears the air surrounding the stigma of synthetic cannabinoids.
Here, Professor Edvinas Orentas, Department of Organic Chemistry, Vilnius University, Lithuania and Head of Research at Sanobiotec, discusses the stigma of synthetic cannabinoids and its benefits.
Synthetic cannabinoids have been labeled as “low quality” compared to their natural cannabinoid counterparts. On the contrary, laboratory-produced cannabinoids are just as effective as the natural versions. In this interview, Professor Edvinas Orentas, Department of Organic Chemistry, Vilnius University, Lithuania and Head of Research at Sanobiotec, clears the air surrounding the stigma of synthetic cannabinoids.
How did you get involved in the cannabis industry?
Professor Edvinas Orentas: Quite accidentally. I was contacted by my colleague asking me to join a newly established company (Sanobiotec) and to help develop a research and development (R&D) department for natural product synthesis. I responded positively, largely driven by the possibility to apply the know-how from the academia world to a meaningful practical context and also to contribute to the creation of inspiring environment for young researchers graduating from the university and seeking for industrial career. So far, it has been an inspiring experience that enriched and educated me in multiple ways.
Can you tell us a little bit about Sanobiotec?
Orentas: Sanobiotec is focused on researching and developing a broader range of cannabinoid applications across pharmaceutical and wellness industries, including both mainstream and rare cannabinoids. A major part of our work revolves around combining the capabilities of synthesis, biosynthesis, and natural extraction which enables the development of optimal production methods for each compound, leading to high-quality products. We operate in a state-of-the-art European Union (EU) good manufacturing practices (GMP) compliant facility, which consists of a cutting-edge synthesis lab, CO2 extraction and purification facility, and an analytics laboratory.
What are “natural” and “synthetic” cannabinoids? Is there a distinct difference between the two?
Orentas: The natural cannabinoids are typically defined as the ones separated from natural sources, in this case the C. sativa plant and all the variations of the species. The fully synthetic cannabinoids are made in the laboratory from scratch, using simple chemical precursors via a multistep process called chemical synthesis. In special cases, you might as well have semi-synthetic cannabinoids, where the starting material comes from the plant and is further elaborated in the lab to another compound.
Synthetic cannabinoids are often viewed as “low quality,” do these cannabinoids surpass their natural counterparts?
Orentas: The “low quality” is not an intrinsic property of neither natural nor synthetic cannabinoid. It merely describes a material that has not been purified properly. At the molecular level, there is no difference whatsoever between a synthetically produced and a natural cannabinoid.
Do you see a stigma surrounding synthetic cannabinoids? If so, how do you overcome it?
Orentas: I see a stigma surrounding all synthetic materials, not only cannabinoids. It is a part of a general phenomenon, known as chemophobia. All artificial chemicals are often subject of demonization, considered being inferior to natural counterparts or even harmful. This ungrounded assumption might have truly devastating consequences. People tend to accept all bioactive natural compounds as perfectly safe and show little concern in using various extracts or teas in large amounts. Ironically, the most toxic compounds known to human are natural, not synthetic. The misconception of natural versus synthetic is further enhanced by various environmental movements (which, by itself, is not a bad thing) and marketing tricks, resulting in such absurdities as chemical-free products.
The best way to fight back this phobia is with education, preferably starting with high school students, explaining the concept and properties of molecules in a comprehensible way. Educating consumers to make smarter, scientifically-based choices, and putting more strict regulations on product labeling might be effective measures as well.
Are environmental factors such as pollutants
and pesticides more commonly found in either cannabinoids?
Orentas: Contamination with pesticides is almost always a concern with natural cannabinoids. They enter the plants from the environment and get amplified thousand-fold during extraction process. These impurities are not typically found in synthetic analogues, as long as sufficiently pure chemicals are used in the synthesis process.
Are natural and synthetic cannabinoids extracted using similar methods?
Orentas: The extraction is an essential process for purifying both natural and synthetic cannabinoids. For extracting natural cannabinoids, very often supercritical CO2 is used as a solvent. This solvent has many advantages, including low toxicity and ease of evaporation. In case of synthetic cannabinoids, extraction process is used throughout the whole synthetic sequence, typically using organic solvents. This necessitates a thorough quality check to precisely monitor the residual amount of the solvent. However, the same strict quality requirements apply for natural cannabinoids as well, since organic solvents are used for final purification step via crystallization.
What advantages are there to using synthetic cannabinoids? Are there disadvantages?
Orentas: Synthetic cannabinoids can be produced on a large scale, starting from relatively simple and cheap commodity chemicals. In this way energy, labor, and land-intensive planting process is omitted. In addition, the quality and the yield of the material is more reproducible and is not a subject to seasonal variations or above-mentioned contamination with pesticides. Unfortunately, for some cannabinoids of very complex structure, there is a lack of efficient synthetic methods or the synthesis is economically unfeasible.
Why does the pharmaceutical industry prefer using synthetic over natural cannabinoids?
Orentas: The chemical synthesis based on a well-developed and robust method is highly reproducible and most of the possible impurities are well-known and traceable. The risk of biological contamination is also greatly reduced using fully synthetic compounds, especially those of GMP-grade.
Is there a disregard to GMPs when using natural cannabinoids?
Orentas: Well, GMP is not a requirement for every product containing natural cannabinoids, unless it is used in very sensitive experimental set-ups, such as clinical trials. Also, it cost a fortune to implement GMP protocols, and not every company can afford it.
Are synthetic cannabinoids analyzed more than natural versions for impurities?
Orentas: In my opinion, the same strict requirements on quality control should apply for both materials. In addition, contamination with pesticides is more likely to occur in natural cannabinoids.
Are there different testing standards for natural and synthetic cannabinoids?
Orentas: Essentially, we are analyzing the same molecule, therefore the procedure and testing standards should be the same.
Are there any forms of regulation or legislation that affect your work?
Orentas: Surely, some of the cannabinoids belong to a special list of regulated substances, and all procedures that involve hemp processing in the company are subject to approved state regulations. Hemp processing can only be done for scientific purposes in Lithuania.
That said, it may be a good time to review some of the regulatory requirements, to better reflect the latest scientific research. Currently, cannabinoids are positioned under Schedule I controlled substances, which are deemed as addiction-inducing, which is not the case with these compounds. Given the possible health benefits of cannabinoids, reclassifying them may propel research going further.
Is there anything that you would like to see change in the future for the cannabis industry?
Orentas: The market is getting saturated with some cannabinoids, especially cannabidiol (CBD), and as a chemist, I think we are in a perfect position to start exploring them as starting material for further structural modifications. The chemical space of possible derivatives is enormous and I’m sure thrilling discoveries are in front of us.
If you would like to be considered for an interview with Cannabis Science and Technology, please reach out to
Madeline Colli, Associate Editor, at
mcolli@mjhlifesciences.com
How to Cite this Article
M. Colli, Cannabis Science and Technology 4(4), 43-44 (2021).
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.